• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.

作者信息

Casadevall Arturo, Pirofski Liise-Anne

机构信息

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, United States of America; Department of Medicine (Infectious Diseases), Albert Einstein College of Medicine, New York, New York, United States of America.

出版信息

PLoS Pathog. 2015 Apr 23;11(4):e1004717. doi: 10.1371/journal.ppat.1004717. eCollection 2015 Apr.

DOI:10.1371/journal.ppat.1004717
PMID:25905897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4408073/
Abstract
摘要

相似文献

1
The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.埃博拉疫情凸显了被动抗体疗法在治疗传染病方面的潜力。
PLoS Pathog. 2015 Apr 23;11(4):e1004717. doi: 10.1371/journal.ppat.1004717. eCollection 2015 Apr.
2
Ebola veteran promises an end to Congo's epidemic.埃博拉疫情“老兵”承诺终结刚果疫情。
Science. 2019 Aug 9;365(6453):526-527. doi: 10.1126/science.365.6453.526.
3
Infectious diseases. In Guinea, a long, difficult road to zero Ebola cases.传染病。在几内亚，实现埃博拉病例零新增的道路漫长而艰难。
Science. 2015 May 1;348(6234):485-6. doi: 10.1126/science.348.6234.485. Epub 2015 Apr 30.
4
Infectious disease: Mobilizing Ebola survivors to curb the epidemic.传染病：动员埃博拉幸存者遏制疫情。
Nature. 2014 Dec 18;516(7531):323-5. doi: 10.1038/516323a.
5
Ebola virus disease epidemic.埃博拉病毒病疫情
Workplace Health Saf. 2014 Nov;62(11):484. doi: 10.3928/21650799-20141014-02.
6
Preparing for the next Ebola epidemic.为下一次埃博拉疫情做准备。
Curr Biol. 2018 Jan 22;28(2):R51-R54. doi: 10.1016/j.cub.2018.01.011. Epub 2018 Jan 31.
7
The Ebola Epidemic. High hopes for Guinean vaccine trial.埃博拉疫情。几内亚疫苗试验寄予厚望。
Science. 2015 Jan 16;347(6219):219-20. doi: 10.1126/science.347.6219.219.
8
Design Improvements for Personal Protective Equipment Used in Ebola and Other Epidemic Outbreaks.用于埃博拉和其他传染病暴发的个人防护设备的设计改进。
Glob Health Sci Pract. 2017 Jun 27;5(2):325-328. doi: 10.9745/GHSP-D-17-00152.
9
Uganda gears up to contain Ebola epidemic as fears of spread cause panic.随着对埃博拉疫情蔓延的担忧引发恐慌，乌干达准备好控制疫情。
BMJ. 2012 Aug 1;345:e5210. doi: 10.1136/bmj.e5210.
10
Critical Choices for the WHO After the Ebola Epidemic.埃博拉疫情后世界卫生组织面临的关键抉择
JAMA. 2015 Jul 14;314(2):113-4. doi: 10.1001/jama.2015.6940.

引用本文的文献

1
Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.外泌体对 COVID-19 的多种影响：从传播到治疗发展的进展视角。
Front Immunol. 2021 Jul 28;12:716407. doi: 10.3389/fimmu.2021.716407. eCollection 2021.
2
Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.释放基于细胞膜的纳米粒子在 COVID-19 治疗和疫苗接种方面的潜力。
Expert Opin Drug Deliv. 2021 Oct;18(10):1395-1414. doi: 10.1080/17425247.2021.1922387. Epub 2021 Jun 6.
3
Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era.新冠疫情时代下单克隆抗体（mAb）发现和开发的量子飞跃。
Semin Immunol. 2020 Aug;50:101427. doi: 10.1016/j.smim.2020.101427. Epub 2020 Nov 17.
4
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）/COVID-19 及其相关疗法和疫苗的研究进展，以应对这一新兴的大流行病。
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40. doi: 10.1186/s12941-020-00384-w.
5
Advances and challenges in the prevention and treatment of COVID-19.COVID-19 的预防和治疗的进展与挑战。
Int J Med Sci. 2020 Jul 9;17(12):1803-1810. doi: 10.7150/ijms.47836. eCollection 2020.
6
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.将氯喹重新定位为预防 COVID-19 的抗病毒药物：潜力与挑战。
Drug Discov Today. 2020 Oct;25(10):1786-1792. doi: 10.1016/j.drudis.2020.06.030. Epub 2020 Jul 3.
7
Emergence of novel coronavirus and progress toward treatment and vaccine.新型冠状病毒的出现以及治疗和疫苗的研发进展。
Rev Med Virol. 2020 Jul;30(4):e2116. doi: 10.1002/rmv.2116. Epub 2020 Jun 4.
8
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.了解新型冠状病毒肺炎：其对器官衰竭的影响及对糖尿病和癌症患者的风险评估。
Cytokine Growth Factor Rev. 2020 Jun;53:43-52. doi: 10.1016/j.cytogfr.2020.05.001. Epub 2020 May 6.
9
Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China.新冠病毒病（COVID-19）的鉴定和管理方面最初取得的成功表明，在中国武汉存在人与人之间的传播。
Int J Biol Sci. 2020 Apr 6;16(11):1846-1860. doi: 10.7150/ijbs.45018. eCollection 2020.
10
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.针对源自中国武汉的新型冠状病毒在疫情爆发情况下的治疗策略。
F1000Res. 2020 Jan 31;9:72. doi: 10.12688/f1000research.22211.2. eCollection 2020.

本文引用的文献

1
Recognition determinants of broadly neutralizing human antibodies against dengue viruses.广谱中和人抗登革病毒抗体的识别决定因素。
Nature. 2015 Apr 2;520(7545):109-13. doi: 10.1038/nature14130. Epub 2015 Jan 12.
2
Ebola raises profile of blood-based therapy.埃博拉提升了基于血液疗法的关注度。
Nature. 2015 Jan 1;517(7532):9-10. doi: 10.1038/517009a.
3
Update: ebola virus disease epidemic - West Africa, December 2014.更新：2014年12月西非埃博拉病毒病疫情
MMWR Morb Mortal Wkly Rep. 2014 Dec 19;63(50):1199-201.
4
Plant-based vaccines against viruses.基于植物的病毒疫苗。
Virol J. 2014 Dec 3;11:205. doi: 10.1186/s12985-014-0205-0.
5
Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease?来自接种过埃博拉病毒病疫苗的健康个体的超免疫血清？
Lancet Glob Health. 2014 Dec;2(12):e686. doi: 10.1016/S2214-109X(14)70341-9. Epub 2014 Oct 30.
6
Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.广谱中和抗 HIV-1 抗体需要 Fc 效应功能才能在体内发挥作用。
Cell. 2014 Sep 11;158(6):1243-1253. doi: 10.1016/j.cell.2014.08.023.
7
A practical treatment for patients with Ebola virus disease.埃博拉病毒病患者的一种实用治疗方法。
J Infect Dis. 2015 Feb 15;211(4):661-2. doi: 10.1093/infdis/jiu474. Epub 2014 Aug 25.
8
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.多效性 Fc 效应子谱由 IgG 亚类选择介导，可区分 RV144 和 VAX003 疫苗。
Sci Transl Med. 2014 Mar 19;6(228):228ra38. doi: 10.1126/scitranslmed.3007736.
9
Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).苏丹埃博拉病毒（Gulu）感染者体内病毒特异性中和性体液免疫应答的特征和持久性。
J Infect Dis. 2013 Jul 15;208(2):299-309. doi: 10.1093/infdis/jit162. Epub 2013 Apr 12.
10
Which are the antibodies to watch in 2013?2013 年需要关注哪些抗体？
MAbs. 2013 Jan-Feb;5(1):1-4. doi: 10.4161/mabs.22976. Epub 2012 Dec 19.